| Base case | Alternative scenarios, changes apply from 1 January 2022 onwards |
---|---|---|
Vaccination coverage in girlsa | 55% | 60%, 70%, 80%, 90%, 90%b |
Vaccine type | Bivalent | Nonavalent |
Screening coveragec | 61% | 70% Stop screening for all women |
Number of lifetime screens for either vaccinated women or vaccinated cohorts (screening ages) | 5 (at 30, 35, 40, 45d, 50, 55d, 60, and 65d years) [13] | 0 (No screening) 1 (at 40Â years) [29] 2 (at 35 and 45Â years) [1] 3 (at 35, 47 and 59Â years) [29] |